BEIJING, Nov. 14 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ('Lotus' or the 'Company'), a pharmaceutical
company in the People's Republic of China ('PRC'), today announced that it
will conduct a conference call at 9:00 a.m. Eastern Standard Time on Tuesday,
November 18, 2008 to discuss results for the quarter ended September 30, 2008.
Joining Dr. Zhongyi Liu, Chairman and Chief Executive Officer of Lotus
Pharmaceuticals, will be Mr. Adam Wasserman, Chief Financial Officer.
To participate in this live conference call, please dial 866 800-8648 five
to ten minutes prior to the scheduled conference call time. International
callers should dial 617 614-2702. The conference Passcode is 151 721 84.
For those who are unable to participate in the conference call at the time
of the call, a replay will be available for fourteen days starting on November
18, at 11:00 a.m. Eastern Standard Time. To access the replay, please dial
888 286-8010. International callers should dial 617 801-6888. The replay
Passcode is 346 912 68.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical
Company, Ltd. ('Liang Fang') and En Ze Jia Shi Pharmaceutical Company, Ltd.
('En Ze'), two pharmaceutical companies located in Beijing, China. Together,
Liang Fang and En Ze form an operating company (together, 'Lotus East').
Lotus East engages in the development of new drugs, drug manufacturing, and
the marketing and sales of pharmaceuticals. Lotus East has advanced
pharmaceutical production equipment with which it produces a portfolio of
pharmaceutical products, and meets National GMP. Lotus East has a number of
highly skilled scientists, 2,000 square meters of office space and a 1,000
square meter warehouse. It operates ten retail pharmacies in the Beijing area.
Safe Harbor Statement
This press release contains 'forward-looking statements' within the
meaning of the 'safe-harbor' provisions of the Private Securities Litigation
Reform Act of 1995. Such statements involve known and unknown risks,
uncertainties and other factors that could cause the actual results of the
Company to differ materially from the results expressed or implied by such
statements, including changes from anticipated levels of sales, future
national or regional economic and competitive and regulatory conditions,
changes in relationships with customers, access to capital, difficulties in
developing and marketing new products, marketing existing products, customer
acceptance of existing and new products, and other factors. Additional
information regarding risks can be found in the Company's Annual Report on
Form 10K filed with the SEC. Accordingly, although the Company believes that
the expectations reflected in such forward-looking statements are reasonable,
there can be no assurance that such expectations will prove to be correct.
The Company has no obligation to update the forward-looking information
contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Mr. Adam Wasserman, CFO
Phone: +1-877-801-0344
Email: info@LotusEast.com
Web site: http://www.lotuseast.com
CCG Investor Relations Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Web site: http://www.ccgirasia.com
SOURCE Lotus Pharmaceuticals, Inc.
